AKESO INC. O.N. (4RY) - Net Assets
Based on the latest financial reports, AKESO INC. O.N. (4RY) has net assets worth €- EUR as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AKESO INC. O.N. - Net Assets Trend (None–None)
This chart illustrates how AKESO INC. O.N.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AKESO INC. O.N. (None–None)
The table below shows the annual net assets of AKESO INC. O.N. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to AKESO INC. O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
AKESO INC. O.N. Competitors by Market Cap
The table below lists competitors of AKESO INC. O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mueller Industries Inc
NYSE:MLI
|
$12.41 Billion |
|
Orkla ASA
OL:ORK
|
$12.42 Billion |
|
United States Steel Corporation
NYSE:X
|
$12.42 Billion |
|
Hyundai Heavy Industries Holdings Co Ltd
KO:267250
|
$12.43 Billion |
|
CITIC Pacific Special Steel Group Co Ltd
SHE:000708
|
$12.36 Billion |
|
Globus Medical
NYSE:GMED
|
$12.36 Billion |
|
Julius Baer Gruppe AG
SW:BAER
|
$12.36 Billion |
|
LPP S.A.
WAR:LPP
|
$12.36 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AKESO INC. O.N.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares AKESO INC. O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently AKESO INC. O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares AKESO INC. O.N.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $224,256,589
- Average return on equity (ROE) among peers: -815.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AKESO INC. O.N. (4RY) | €- | N/A | N/A | $12.38 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $24.67 Million |
| PreveCeutical Medical Inc (18H) | $-296.06K | 0.00% | 0.00x | $3.34 Million |
| IDORSIA AG (19T) | $-1.21 Billion | 0.00% | 0.00x | $978.02 Million |
| ONCOARENDI THERAP ZY-01 (1B1) | $100.93 Million | -28.11% | 0.11x | $24.94 Million |
| Flerie AB (publ) (1NP1) | $3.38 Billion | -22.41% | 0.01x | $231.62 Million |
| NUFORMIX PLC LS -001 (1RT) | $5.69 Million | -22.04% | 0.06x | $1.53 Million |
| 1S90 (1S90) | $44.22 Million | 12.88% | 2.13x | $70.17 Million |
| Strategic Partners A/S (1TB0) | $9.34 Million | -6708.84% | 17.55x | $3.69 Million |
| Entheon Biomedical Corp. (1XU) | $614.57K | -1386.45% | 0.25x | $502.28K |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $125.12 Million |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and nec… Read more